Status:
COMPLETED
Ifosfamide/Carboplatin/Etoposide/Rituxan Followed by Zevalin in Relapsed/Refractory Intermediate Grade B-Cell Lymphoma
Lead Sponsor:
SCRI Development Innovations, LLC
Collaborating Sponsors:
Biogen
Conditions:
Non-Hodgkins Lymphoma
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
In this Multicenter trial, we will evaluate the feasibility, toxicity, and efficacy of treatment with 90Y Zevalin following a short course of salvage chemotherapy in patients with relapsed/refractory ...
Detailed Description
Upon determination of eligibility, patients will receive: * Ifosfamide + Carboplatin + Etoposide + Rituximab Patients showing no response to this combination regimen will receive 90Y Zevalin after t...
Eligibility Criteria
Inclusion
- To be included in this study, you must meet the following criteria:
- Intermediate grade CD20-positive B-cell non-Hodgkin's lymphoma
- Persistent lymphoma after one or two previous chemotherapy regimens
- Patients should not be considered candidates for high-dose chemotherapy
- Ability to perform activities of daily living with assistance
- Measurable or evaluable disease
- Age \> 18 years
- Adequate bone marrow, liver and kidney function
Exclusion
- You cannot participate in this study if any of the following apply to you:
- Patients with impaired bone marrow reserve
- Female patients who are pregnant or lactating
- Serious active infection at the time of treatment
- Any other serious underlying condition
- Brain or meningeal) with lymphoma
- HIV or AIDS-related lymphoma
- Received external beam radiation therapy to \> 25% of active bone marrow.
- History of other cancers, either active or treated
- Please note: There are additional inclusion/exclusion criteria. The study center will determine if you meet all of the criteria. If you do not qualify for the trial, study personnel will explain the reasons. If you do qualify, study personnel will explain the trial in detail and answer any questions you may have.
Key Trial Info
Start Date :
October 1 2003
Trial Type :
INTERVENTIONAL
End Date :
August 1 2005
Estimated Enrollment :
40 Patients enrolled
Trial Details
Trial ID
NCT00193505
Start Date
October 1 2003
End Date
August 1 2005
Last Update
May 3 2011
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Tennessee Oncology, PLLC
Nashville, Tennessee, United States, 37023